Drug intelligence / Profile preview

oxycodone + oxycodone extended-release

Development stage: Unknown
Lead developer: Purdue Pharma
Modality: Small Molecules
Administration: Oral

Overview

Oxycodone is a potent semisynthetic opioid analgesic used to relieve severe pain. It comes in immediate-release and extended-release formulations. The extended-release versions (such as OxyContin and Xtampza ER) are designed to provide pain relief over 12 hours, requiring fewer daily doses compared to immediate-release formulations. Oxycodone works by binding to opioid receptors in the central nervous system and periphery, primarily mu-opioid receptors, inhibiting pain responses by changing how the brain and nervous system respond to pain.

Brand names: OxyContinXtampza ERDazidoxEth-OxydoseOxaydoOxydoseOxyfastOxy IRRoxicodoneRoxicodone IntensolRoxybond

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on oxycodone + oxycodone extended-release.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxycodone + oxycodone extended-release.

Explore the full profile